Kirstie Lamb

Ms. Kirstie Lamb


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
KLKirstie Lamb
Kirstie Lamb
MRMayur Krachna Ranchordas
Mayur Krachna Ranchordas
EJElizabeth Johnson
Elizabeth Johnson
JDJessica Denning
Jessica Denning
FDFaye Downing
Faye Downing
ALAnthony Lynn
Anthony Lynn
Tart cherry juice (TC) and pomegranate juice (POM) have been demonstrated to reduce symptoms of exercise-induced muscle damage (EIMD), but their effectiveness has not been compared. This randomized, double-blind, parallel study compared the effects of TC and POM on markers of EIMD. Thirty-six non-resistance trained men (age 24.0 (Interquartile Range (IQR) 22.0, 33.0) years, body mass index (BMI) 25.6 ± 4.0 kg·m−2) were randomly allocated to consume 2 × 250 mL of: TC, POM, or an energy-matched fruit-flavored placebo drink twice daily for nine days. On day 5, participants undertook eccentric exercise of the elbow flexors of their non-dominant arm. Pre-exercise, immediately post-exercise, and at 24 h, 48 h, 72 h and 96 h post-exercise, maximal isometric voluntary contraction (MIVC), delayed onset muscle soreness (DOMS), creatine kinase (CK), and range of motion (ROM) were measured. The exercise protocol induced significant decreases in MIVC (p < 0.001; max decrease of 26.8%, 24 h post-exercise) and ROM (p = 0.001; max decrease of 6.8%, 72 h post-exercise) and significant increases in CK (p = 0.03; max increase 1385 U·L−1, 96 h post-exercise) and DOMS (p < 0.001; max increase of 26.9 mm, 48 h post-exercise). However, there were no statistically significant differences between treatment groups (main effect of group p > 0.05 or group x time interaction p > 0.05). These data suggest that in non-resistance trained men, neither TC nor POM enhance recovery from high-force eccentric exercise of the elbow flexors.

15 March 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
KLKirstie Lamb
Kirstie Lamb
ALAnthony Lynn
Anthony Lynn
JRJean Russell
Jean Russell
MBMargo E Barker
Margo E Barker
Introduction Gout is a painful form of inflammatory arthritis associated with several comorbidities, particularly cardiovascular disease. Cherries, which are rich in anti-inflammatory and antioxidative bioactive compounds, are proposed to be efficacious in preventing and treating gout, but recommendations to patients are conflicting. Cherry consumption has been demonstrated to lower serum urate levels and inflammation in several small studies. One observational case cross-over study reported that cherry consumption was associated with reduced risk of recurrent gout attacks. This preliminary evidence requires substantiation. The proposed randomised clinical trial aims to test the effect of consumption of tart cherry juice on risk of gout attacks. Methods and analysis This 12-month, parallel, double-blind, randomised, placebo-controlled trial will recruit 120 individuals (aged 18–80 years) with a clinical diagnosis of gout who have self-reported a gout flare in the previous year. Participants will be randomly assigned to an intervention group, which will receive Montmorency tart cherry juice daily for a 12-month period, or a corresponding placebo group, which will receive a cherry-flavoured placebo drink. The primary study outcome is change in frequency of self-reported gout attacks. Secondary outcome measures include attack intensity, serum urate concentration, fractional excretion of uric acid, biomarkers of inflammation, blood lipids and other markers of cardiovascular risk. Other secondary outcome measures will be changes in physical activity and functional status. Statistical analysis will be conducted on an intention-to-treat basis. Ethics and dissemination This study has been granted ethical approval by the National Research Ethics Service, Yorkshire and The Humber—Leeds West Research Ethics Committee (ref: 18/SW/0262). Results of the trial will be submitted for publication in a peer-reviewed journal. Trial registration number NCT03621215.

14 August 2023 in Public Health Nutrition
Verified
Journal Article
Open access
PDF file
KLKirstie Lamb
Kirstie Lamb
MBMargo E Barker
Margo E Barker
ALAnthony Lynn
Anthony Lynn
Objective: To assess the alignment of YouTube® videos providing dietary recommendations for gout with evidence-based guidelines targeted at the United Kingdom (UK) population and to establish their quality.Design: A content analysis of YouTube® videos providing dietary recommendations for gout was undertaken. Videos were categorised by video source. Each video’s dietary recommendations for gout were compared with three evidence-based guidelines for gout, producing a compliance score. Presence of non-guideline advice was assessed. Understandability and actionability were evaluated using the Patient Education Material Assessment Tool for Audio-Visual Materials. Reliability was assessed using an adapted-DISCERN tool and educational quality using the Global Quality Score Five-Point Scale. Differences between video source and continuous variables were assessed using one-way Kruskal–Wallis H tests. For categorical variables, associations were investigated using Fisher–Freeman–Halton tests.Setting: Online, May–June 2020.Participants: One-hundred thirty-one videos.Results: Alignment of videos with evidence-based guidelines was poor (median compliance score 27 % (interquartile range 17–37 %)). Additionally, 57 % of videos contained non-guideline advice. The health professional source group had the fewest videos containing non-guideline advice, but this was only significantly lower than the naturopath group (31 % v. 81 %, P = 0·009). Almost 70 % of videos were considered poorly actionable and 50 % poorly understandable. Most videos were rated poor for reliability (79 %) and poor to generally poor for educational quality (49 %).Conclusions: YouTube® videos providing dietary recommendations for gout frequently fail to conform to evidence-based guidelines, and their educational quality, reliability, understandability and actionability are often poor. More high-quality, comprehensive, evidence-based YouTube® videos are required for UK gout patients.

28 January 2026 in Nutrition and Health
Verified
Journal Article
Open access
KLKirstie Lamb
Kirstie Lamb
ALAnthony Lynn
Anthony Lynn
Background: Hyperuricaemia increases the risk of gout, and cardiovascular disease, thus dietary modifications that reduce urate are of interest. Cherries have been reported to lower urate, but studies examining acute effects have mostly failed to include a control group, despite urate being known to exhibit diurnal fluctuations, typically falling throughout the day. Aim: This study aimed to determine the acute effects of a single serving of tart cherry juice on uric acid metabolism and risk factors for cardiovascular disease relative to a control drink. Methods: In an open-label, randomised, controlled, crossover design, 12 healthy adults (mean age 41.1 (±11.1) y; mean body mass index 26.4 (±4.3) kg/m 2 ; 7 men and 5 women) consumed 250 mL tart cherry juice (containing 30 mL of concentrate) and 250 mL water (control) on separate occasions ≥7 days apart. Serum uric acid, central and brachial blood pressure, augmentation index and pulse wave velocity were measured at baseline, 1, 2, 3, 5 and 24 h, post-drink, serum C-reactive protein at baseline, 2 and 5 h, and creatinine-adjusted urinary uric acid at 0 to 2, 2 to 4 and 4 to 5 h. Results: There were no statistically significant main effects of drink type or drink by time interactions (all outcomes p > 0.05). However, independent of drink type, serum uric acid ( p = 0.008), urinary uric acid ( p < 0.001), C-reactive protein ( p = 0.023) and measures of blood pressure (all p < 0.05) changed with different temporal patterns throughout the day (main effects of time, p < 0.05). Conclusion: These results indicate that diurnal fluctuations may partly explain the beneficial acute effects of cherry consumption on uric acid metabolism and inflammation previously reported in studies without a comparator control group.